The broad objective of this proposal is to identify combinatorial vaccine approaches that will result in effective immunization against breast cancer. Immune tolerance mechanisms (systemic and at the tumor site) provide formidable barriers to effective immunization in cancer patients. HER-2/neu transgenic (neu-N) mice demonstrate immune tolerance to the endogenously expressed rat HER-2/neu (neu) protein. We have successfully used these mice to define systemic tolerance mechanisms and to identify combinatorial vaccine approaches that can overcome them. We recently identified RNEU42o-429 as the immunodominant MHC I epitope in rat neu. RNEU42o^29-specific T cells isolated from vaccinated neu-N mice exhibit lower avidity than T cells isolated from the parental non-tolerized mice (FVB/N). Immune modulating doses of Cyclophosphamide (Cy) in sequence with vaccine in neu-N mice produce RNEU42o-429-specific T cells that have 10-fold higher avidity as compared to T cells from neu-N mice given vaccine alone. The enhanced avidity of the T cells correlates with the mouse's ability to reject neu-expressing mammary tumors. Modulation of additional mechanisms of systemic T cell tolerance together with the modulation of mechanisms of immune tolerance in the tumor's microenvironment in these mice, should lead to the development of new and improved combinatorial immunotherapy strategies for the treatment of breast cancer patients.
In aim 1, we will evaluate immune modulating agents that will effectively activate neuspecific CD8+ T cell populations specific for the non-dominant neu epitopes..
In aim 2, we will evaluate immune modulating agents that will effectively activate low avidity neu-specific CD8+ T cell populations specific for the RNEU42o-429 epitope.
In aim 3, we will evaluate pathways within the tumor's microenvironment (two new B7 family members) that are barriers to effective tumor eradication in vivo.
In aim 4, we will evaluate the frequency of expression of these tolerizing signals by human breast cancer specimens.
In aim 5, we will determine the therapeutic value of the most potent immune modulating agent/vaccine combinations in treating spontaneously arising neu-expressing mammary tumors and liver metastases. The most effective combinations identified in aims 1-5, will be tested in patients with breast cancer. However, funding for the clinical trials that arise from this grant will come from other sources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA088843-09
Application #
7902235
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-30
Budget End
2010-09-29
Support Year
9
Fiscal Year
2009
Total Cost
$344,921
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lo, Pang-Kuo (2018) FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells. Trends Diabetes Metab 1:
Cravero, Karen; Medford, Arielle; Pallavajjala, Aparna et al. (2018) Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Pract Lab Med 12:e00108
Connolly, Roisin M; Fackler, Mary Jo; Zhang, Zhe et al. (2018) Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat 167:107-116
Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701
Lo, Pang-Kuo (2017) The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer. PRAS Open 1:
Haffner, Michael C; Esopi, David M; Chaux, Alcides et al. (2017) AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun 8:142
Sunay, Melek M E; Foote, Jeremy B; Leatherman, James M et al. (2017) Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol 46:112-123
Parsons, Heather A; Beaver, Julia A; Cimino-Mathews, Ashley et al. (2017) Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 23:379-386
Cidado, Justin; Wong, Hong Yuen; Rosen, D Marc et al. (2016) Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget 7:6281-93
Lo, Pang-Kuo; Lee, Ji Shin; Liang, Xiaohui et al. (2016) The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression. Cell Signal 28:1502-19

Showing the most recent 10 out of 282 publications